MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$3.05 USD
-0.05 (-1.61%)
Updated Apr 26, 2024 03:44 PM ET
After-Market: $3.08 +0.03 (0.98%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
Balance Sheet
Fiscal Year End for MEI Pharma, Inc falls in the month of June.
All items in Millions except Per Share data.
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 101 | 153 | 153 | 183 | 74 |
Receivables | 0 | 10 | 0 | 20 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 4 | 11 | 6 | 2 |
Total Current Assets | 108 | 167 | 165 | 209 | 82 |
Net Property & Equipment | 1 | 2 | 2 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 121 | 178 | 174 | 210 | 83 |
Liabilities & Shareholders Equity | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 8 | 6 | 2 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 11 | 8 | 6 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 5 | 15 | 15 | 5 |
Total Current Liabilities | 20 | 24 | 30 | 23 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 65 | 91 | 73 | 68 | 3 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 2 | 22 | 40 | 18 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 96 | 125 | 133 | 132 | 35 |
Shareholders Equity | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 431 | 427 | 369 | 355 | 279 |
Retained Earnings | -406 | -374 | -328 | -277 | -231 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 25 | 52 | 41 | 78 | 48 |
Total Liabilities & Shareholder's Equity | 121 | 178 | 174 | 210 | 83 |
Total Common Equity | 25 | 52 | 41 | 78 | 48 |
Shares Outstanding | 6.60 | 6.60 | 5.60 | 5.30 | 3.50 |
Book Value Per Share | 3.73 | 7.94 | 7.39 | 14.76 | 13.69 |
Fiscal Year End for MEI Pharma, Inc falls in the month of June.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 59 | 82 | 101 | 112 |
Receivables | NA | 0 | 0 | 0 | 5 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 7 | 6 | 7 | 4 |
Total Current Assets | NA | 66 | 88 | 108 | 120 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 79 | 101 | 121 | 134 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 3 | 6 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 6 | 4 | 12 | 16 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 2 |
Total Current Liabilities | NA | 8 | 9 | 20 | 24 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 65 | 65 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 19 | 20 | 96 | 100 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 420 | 431 | 431 | 430 |
Retained Earnings | NA | -361 | -350 | -406 | -396 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 59 | 81 | 25 | 34 |
Total Liabilities & Shareholder's Equity | NA | 79 | 101 | 121 | 134 |
Total Common Equity | 0 | 59 | 81 | 25 | 34 |
Shares Outstanding | 6.60 | 6.60 | 6.60 | 6.60 | 6.60 |
Book Value Per Share | 0.00 | 9.01 | 12.33 | 3.73 | 5.20 |